Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05634681
Other study ID # 236807
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 13, 2022
Est. completion date December 31, 2032

Study information

Verified date November 2022
Source Oslo University Hospital
Contact Kjersti Bruheim, MD PhD
Phone +4723934000
Email uxkjuh@ous-hf.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study objectives are to improve the treatment of LACC patients and to increase knowledge of the potential benefit of the plan-of-the-day concept on side effects during and after radiotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 190
Est. completion date December 31, 2032
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed cervical cancer eligible for definitve radiochemotherapy - FIGO stage IB1-IVa - Over 18 years - Speaks and understands Norwegian or English. - ECOG 0-2 - Histology: Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma - Ability to understand and fill in patient questionnaires, and willing to sign a written informed consent - Large movers (LM), fundus movement =2,5 cm. Exclusion Criteria: - Evidence of distant metastasis. Suspicious paraaortic lymphnodes below the renal vessels is allowed if they are covered by the radiation field - Patients with previous surgery for their cervical cancer - Uncontrolled intercurrent somatic illness. - Psychiatric illness /social situations limiting study compliance - Prior radiotherapy to the pelvis - Patients who are pregnant or breastfeeding is excluded due to risk of teratogenic and abortifacient effects of radiotherapy and cisplatin, and the potential risk of adverse effect of nursing infants - Patients under current treatment for other invasive s except non-melanoma skin cancers - Nephrostomy - Patients with inflammatory bowel disease

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Plan of the day
Several treatment plans are prepared and the appropriate plan is used at each treatment session.
Standard plan
One treatment plan

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate whether implementation of the plan of the day concept results in less gastro-intestinal toxicity. To compare the change in patient reported acute diarrhea from baseline to week 4 from start of the treatment and to the end of external radiotherapy.
Item 17 in EORTC QLQ-C30
5 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04067882 - Validation of the Genetic Signature 354849 as a Prognostic Method
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Recruiting NCT05743517 - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) N/A
Completed NCT05234112 - Prevention and Screening Towards Elimination of Cervical Cancer N/A
Completed NCT04258553 - Thiol Disulfide Balance in Cervix Cancer
Completed NCT03956498 - Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy N/A
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Completed NCT00379743 - Partnership for Healthy Seniors N/A
Completed NCT00509444 - Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial Phase 3
Recruiting NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. Phase 1
Recruiting NCT06116019 - Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Active, not recruiting NCT06452004 - Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) N/A
Recruiting NCT04651127 - Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT06010875 - A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors Phase 1
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02997553 - Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Phase 3
Terminated NCT02233387 - PET CT With HX4 in Cervix Cancer Phase 2
Completed NCT01766284 - Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix N/A